Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- NSSC +17.9%, PDD +3.1%, AIIO +1.4%
Other news:
- SBMT +9.6% (signs definitive agreement to acquire the Jefferson County metallurgical complex in Montana)
- BMEA +7.8% (completion of enrollment in COVALENT-211 phase II trial of Icovamenib in insulin-deficient type 2 diabetes)
- SSEA +6% (enters business combination agreement with SuperiorMed Holdings)
- SGML +5.4% (resumes full mining, industrial operations after TAC agreement with Minas Gerais)
- GLUE +4.5% (announces first patient dosed in MODeFIRe-1, a phase 2 study of MRT-2359 in combination with apalutamide in patients with ar mutation-positive metastatic castration-resistant prostate cancer)
- ACAD +2.5% (says EU approves DAYBU for Rett syndrome)
- ENTX +1.9% (files for 134,803,910 ordinary share offering by selling shareholders)
- RGNX +1.7% (says FDA places clinical hold on RGX-121; no near-term BLA resubmission for MPS II program)
- LODE +1.6% (receives $20 million and closes sale of legacy mining assets to Mackay Precious Metals Inc)
- AIB +1.4% (COO Eyal Rozen resigns effective immediately -- 8-K filing)
- OCS +1.3% (treats first patient in PIONEER-1 registrational trial of Privosegtor for optic neuritis; plans IND for acute MS relapses in Q4)
- UTHR +1.3% (FDA accepts ralinepag NDA for PAH; PDUFA set for June 24, 2027)
- CTKB +1.2% (says jury backed it on 3 of 4 patent claims; to challenge $56 mln damages on remaining finding)
- TLSA +1.1% (announces poster presentation on Phase 2a BANYAN clinical trial of intranasal foralumab at ALS Nexus 2026)
- DTIL +1% (doses first patient in Phase 1/2 FUNCTION-DMD study)